These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 24479980)
41. Anti-adhesion molecules: is gut specificity the key for a good safety profile? Allen PB Curr Drug Deliv; 2012 Jul; 9(4):333-7. PubMed ID: 22762276 [TBL] [Abstract][Full Text] [Related]
49. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease. Peng JC; Shen J; Ran ZH J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263 [TBL] [Abstract][Full Text] [Related]
50. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases. Smith MA; Mohammad RA Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623 [TBL] [Abstract][Full Text] [Related]
52. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
53. [Vedolizumab in the treatment of Crohn's disease]. Gisbert JP; Domènech E Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903 [TBL] [Abstract][Full Text] [Related]
54. New drug therapies on the horizon for IBD. Perrier C; Rutgeerts P Dig Dis; 2012; 30 Suppl 1():100-5. PubMed ID: 23075877 [TBL] [Abstract][Full Text] [Related]
55. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Luthra P; Peyrin-Biroulet L; Ford AC Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741 [TBL] [Abstract][Full Text] [Related]
56. [New molecules in the treatment of inflammatory bowel disease]. Chaparro M; Gisbert JP Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943 [TBL] [Abstract][Full Text] [Related]